Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients
We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2006-08, Vol.73 (2), p.150-157 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 157 |
|---|---|
| container_issue | 2 |
| container_start_page | 150 |
| container_title | Diabetes research and clinical practice |
| container_volume | 73 |
| creator | Kitagawa, Nagako Yano, Yutaka Gabazza, Esteban C. Bruno, Nelson E. Araki, Rika Matsumoto, Kazutaka Katsuki, Akira Hori, Yasuko Nakatani, Kaname Taguchi, Osamu Sumida, Yasuhiro Suzuki, Koji Adachi, Yukihiko |
| description | We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type 2 diabetic patients and 31 normal subjects. The intra-abdominal visceral and subcutaneous fat areas were measured by computed tomography (CT). The degree of insulin resistance was evaluated by the euglycemic–hyperinsulinemic clamp technique using artificial pancreas. The plasma levels of TAFI (169.0
±
108.8% versus 103.7
±
52.3%;
p
<
0.001, mean
±
S.D.) and PAI-1 (82.7
±
54.5
ng/ml versus 52.9
±
51.7
ng/ml;
p
<
0.05) were significantly higher in non-obese type 2 diabetic patients than in normal subjects. Univariate analysis showed that the plasma TAFI levels are significantly and inversely correlated with the glucose infusion rate (GIR) (
r
=
−0.42,
p
<
0.005) in all diabetic patients. Moreover, the plasma levels of TAFI were significantly correlated with fasting plasma glucose levels (
r
=
0.47,
p
<
0.001) and HbA
1c (
r
=
0.38,
p
<
0.005) in all subjects. The plasma levels of PAI-1 were significantly and proportionally correlated with the visceral fat area (
r
=
0.42,
p
<
0.005) and body mass index (
r
=
0.33,
p
<
0.05). There was no significant correlation between plasma levels of TAFI and PAI-1 (
r
=
0.04). These results show that the plasma levels of TAFI and PAI-1 differently correlate with insulin resistance and visceral fat accumulation, suggesting that different factors are implicated in the plasma elevation of TAFI and PAI-1 in non-obese type 2 diabetes mellitus. |
| doi_str_mv | 10.1016/j.diabres.2005.12.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68594337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822706000076</els_id><sourcerecordid>68594337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-ebfdefe95cb932f04622a345944a624115a7b8d8bd002812642a2dc2278713d83</originalsourceid><addsrcrecordid>eNqFkctuFDEQRS0EIkPgE0BesevGdr88K4TCI5EisYG15UeZ1KjbbmxPpPkWfhYP04IlK5dUp-r61iXkNWctZ3x8d2gdapMgt4KxoeWiZUw-ITsuJ9FIIaanZFc5-ae-Ii9yPjDGxq4fnpMrPvaD7OSwI78-oveQIBS6QNEmzmipjSnBrAvGkGn0tDykuBgMjbYFH3XFZqAeTcIQ51PGTDE8oMESE9XB0XXWeam9HxDoNlI7f5mG15qGGJpoIAMtpxWooGc_UKr8WpXrh_JL8szrOcOr7b0m3z9_-nZz29x__XJ38-G-sb3YlwaMd-BhP1iz74Rn_SiErj73fa9H0XM-6MlIJ41jTEguxl5o4Ww9i5x452R3Td5e9q4p_jxCLmrBbGGedYB4zGqUdVfXTRUcLqBNMecEXq0JF51OijN1TkUd1JaKOqeiuFA1lTr3ZhM4mgXcv6kthgq8vwBQbT4iJJVtPYEFhwlsUS7ifyR-AyQhpIU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68594337</pqid></control><display><type>article</type><title>Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kitagawa, Nagako ; Yano, Yutaka ; Gabazza, Esteban C. ; Bruno, Nelson E. ; Araki, Rika ; Matsumoto, Kazutaka ; Katsuki, Akira ; Hori, Yasuko ; Nakatani, Kaname ; Taguchi, Osamu ; Sumida, Yasuhiro ; Suzuki, Koji ; Adachi, Yukihiko</creator><creatorcontrib>Kitagawa, Nagako ; Yano, Yutaka ; Gabazza, Esteban C. ; Bruno, Nelson E. ; Araki, Rika ; Matsumoto, Kazutaka ; Katsuki, Akira ; Hori, Yasuko ; Nakatani, Kaname ; Taguchi, Osamu ; Sumida, Yasuhiro ; Suzuki, Koji ; Adachi, Yukihiko</creatorcontrib><description><![CDATA[We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type 2 diabetic patients and 31 normal subjects. The intra-abdominal visceral and subcutaneous fat areas were measured by computed tomography (CT). The degree of insulin resistance was evaluated by the euglycemic–hyperinsulinemic clamp technique using artificial pancreas. The plasma levels of TAFI (169.0
±
108.8% versus 103.7
±
52.3%;
p
<
0.001, mean
±
S.D.) and PAI-1 (82.7
±
54.5
ng/ml versus 52.9
±
51.7
ng/ml;
p
<
0.05) were significantly higher in non-obese type 2 diabetic patients than in normal subjects. Univariate analysis showed that the plasma TAFI levels are significantly and inversely correlated with the glucose infusion rate (GIR) (
r
=
−0.42,
p
<
0.005) in all diabetic patients. Moreover, the plasma levels of TAFI were significantly correlated with fasting plasma glucose levels (
r
=
0.47,
p
<
0.001) and HbA
1c (
r
=
0.38,
p
<
0.005) in all subjects. The plasma levels of PAI-1 were significantly and proportionally correlated with the visceral fat area (
r
=
0.42,
p
<
0.005) and body mass index (
r
=
0.33,
p
<
0.05). There was no significant correlation between plasma levels of TAFI and PAI-1 (
r
=
0.04). These results show that the plasma levels of TAFI and PAI-1 differently correlate with insulin resistance and visceral fat accumulation, suggesting that different factors are implicated in the plasma elevation of TAFI and PAI-1 in non-obese type 2 diabetes mellitus.]]></description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2005.12.008</identifier><identifier>PMID: 16458385</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Body Mass Index ; Carboxypeptidase B2 - blood ; Carboxypeptidase B2 - metabolism ; Diabetes Mellitus, Type 2 - metabolism ; Female ; Fibrinolysis ; Humans ; Insulin Resistance ; Intra-Abdominal Fat - anatomy & histology ; Male ; Middle Aged ; Obesity - metabolism ; Plasminogen Activator Inhibitor 1 - blood ; Plasminogen Activator Inhibitor 1 - metabolism ; Type 2 diabetes mellitus ; Visceral fat</subject><ispartof>Diabetes research and clinical practice, 2006-08, Vol.73 (2), p.150-157</ispartof><rights>2006 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-ebfdefe95cb932f04622a345944a624115a7b8d8bd002812642a2dc2278713d83</citedby><cites>FETCH-LOGICAL-c429t-ebfdefe95cb932f04622a345944a624115a7b8d8bd002812642a2dc2278713d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168822706000076$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16458385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kitagawa, Nagako</creatorcontrib><creatorcontrib>Yano, Yutaka</creatorcontrib><creatorcontrib>Gabazza, Esteban C.</creatorcontrib><creatorcontrib>Bruno, Nelson E.</creatorcontrib><creatorcontrib>Araki, Rika</creatorcontrib><creatorcontrib>Matsumoto, Kazutaka</creatorcontrib><creatorcontrib>Katsuki, Akira</creatorcontrib><creatorcontrib>Hori, Yasuko</creatorcontrib><creatorcontrib>Nakatani, Kaname</creatorcontrib><creatorcontrib>Taguchi, Osamu</creatorcontrib><creatorcontrib>Sumida, Yasuhiro</creatorcontrib><creatorcontrib>Suzuki, Koji</creatorcontrib><creatorcontrib>Adachi, Yukihiko</creatorcontrib><title>Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description><![CDATA[We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type 2 diabetic patients and 31 normal subjects. The intra-abdominal visceral and subcutaneous fat areas were measured by computed tomography (CT). The degree of insulin resistance was evaluated by the euglycemic–hyperinsulinemic clamp technique using artificial pancreas. The plasma levels of TAFI (169.0
±
108.8% versus 103.7
±
52.3%;
p
<
0.001, mean
±
S.D.) and PAI-1 (82.7
±
54.5
ng/ml versus 52.9
±
51.7
ng/ml;
p
<
0.05) were significantly higher in non-obese type 2 diabetic patients than in normal subjects. Univariate analysis showed that the plasma TAFI levels are significantly and inversely correlated with the glucose infusion rate (GIR) (
r
=
−0.42,
p
<
0.005) in all diabetic patients. Moreover, the plasma levels of TAFI were significantly correlated with fasting plasma glucose levels (
r
=
0.47,
p
<
0.001) and HbA
1c (
r
=
0.38,
p
<
0.005) in all subjects. The plasma levels of PAI-1 were significantly and proportionally correlated with the visceral fat area (
r
=
0.42,
p
<
0.005) and body mass index (
r
=
0.33,
p
<
0.05). There was no significant correlation between plasma levels of TAFI and PAI-1 (
r
=
0.04). These results show that the plasma levels of TAFI and PAI-1 differently correlate with insulin resistance and visceral fat accumulation, suggesting that different factors are implicated in the plasma elevation of TAFI and PAI-1 in non-obese type 2 diabetes mellitus.]]></description><subject>Body Mass Index</subject><subject>Carboxypeptidase B2 - blood</subject><subject>Carboxypeptidase B2 - metabolism</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Intra-Abdominal Fat - anatomy & histology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity - metabolism</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Type 2 diabetes mellitus</subject><subject>Visceral fat</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctuFDEQRS0EIkPgE0BesevGdr88K4TCI5EisYG15UeZ1KjbbmxPpPkWfhYP04IlK5dUp-r61iXkNWctZ3x8d2gdapMgt4KxoeWiZUw-ITsuJ9FIIaanZFc5-ae-Ii9yPjDGxq4fnpMrPvaD7OSwI78-oveQIBS6QNEmzmipjSnBrAvGkGn0tDykuBgMjbYFH3XFZqAeTcIQ51PGTDE8oMESE9XB0XXWeam9HxDoNlI7f5mG15qGGJpoIAMtpxWooGc_UKr8WpXrh_JL8szrOcOr7b0m3z9_-nZz29x__XJ38-G-sb3YlwaMd-BhP1iz74Rn_SiErj73fa9H0XM-6MlIJ41jTEguxl5o4Ww9i5x452R3Td5e9q4p_jxCLmrBbGGedYB4zGqUdVfXTRUcLqBNMecEXq0JF51OijN1TkUd1JaKOqeiuFA1lTr3ZhM4mgXcv6kthgq8vwBQbT4iJJVtPYEFhwlsUS7ifyR-AyQhpIU</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Kitagawa, Nagako</creator><creator>Yano, Yutaka</creator><creator>Gabazza, Esteban C.</creator><creator>Bruno, Nelson E.</creator><creator>Araki, Rika</creator><creator>Matsumoto, Kazutaka</creator><creator>Katsuki, Akira</creator><creator>Hori, Yasuko</creator><creator>Nakatani, Kaname</creator><creator>Taguchi, Osamu</creator><creator>Sumida, Yasuhiro</creator><creator>Suzuki, Koji</creator><creator>Adachi, Yukihiko</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients</title><author>Kitagawa, Nagako ; Yano, Yutaka ; Gabazza, Esteban C. ; Bruno, Nelson E. ; Araki, Rika ; Matsumoto, Kazutaka ; Katsuki, Akira ; Hori, Yasuko ; Nakatani, Kaname ; Taguchi, Osamu ; Sumida, Yasuhiro ; Suzuki, Koji ; Adachi, Yukihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-ebfdefe95cb932f04622a345944a624115a7b8d8bd002812642a2dc2278713d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Body Mass Index</topic><topic>Carboxypeptidase B2 - blood</topic><topic>Carboxypeptidase B2 - metabolism</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Intra-Abdominal Fat - anatomy & histology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity - metabolism</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Type 2 diabetes mellitus</topic><topic>Visceral fat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kitagawa, Nagako</creatorcontrib><creatorcontrib>Yano, Yutaka</creatorcontrib><creatorcontrib>Gabazza, Esteban C.</creatorcontrib><creatorcontrib>Bruno, Nelson E.</creatorcontrib><creatorcontrib>Araki, Rika</creatorcontrib><creatorcontrib>Matsumoto, Kazutaka</creatorcontrib><creatorcontrib>Katsuki, Akira</creatorcontrib><creatorcontrib>Hori, Yasuko</creatorcontrib><creatorcontrib>Nakatani, Kaname</creatorcontrib><creatorcontrib>Taguchi, Osamu</creatorcontrib><creatorcontrib>Sumida, Yasuhiro</creatorcontrib><creatorcontrib>Suzuki, Koji</creatorcontrib><creatorcontrib>Adachi, Yukihiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kitagawa, Nagako</au><au>Yano, Yutaka</au><au>Gabazza, Esteban C.</au><au>Bruno, Nelson E.</au><au>Araki, Rika</au><au>Matsumoto, Kazutaka</au><au>Katsuki, Akira</au><au>Hori, Yasuko</au><au>Nakatani, Kaname</au><au>Taguchi, Osamu</au><au>Sumida, Yasuhiro</au><au>Suzuki, Koji</au><au>Adachi, Yukihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>73</volume><issue>2</issue><spage>150</spage><epage>157</epage><pages>150-157</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract><![CDATA[We investigated the plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) and their relation with clinical and metabolic parameters in non-obese type 2 diabetic patients. The plasma levels of TAFI and PAI-1 were evaluated in 47 non-obese type 2 diabetic patients and 31 normal subjects. The intra-abdominal visceral and subcutaneous fat areas were measured by computed tomography (CT). The degree of insulin resistance was evaluated by the euglycemic–hyperinsulinemic clamp technique using artificial pancreas. The plasma levels of TAFI (169.0
±
108.8% versus 103.7
±
52.3%;
p
<
0.001, mean
±
S.D.) and PAI-1 (82.7
±
54.5
ng/ml versus 52.9
±
51.7
ng/ml;
p
<
0.05) were significantly higher in non-obese type 2 diabetic patients than in normal subjects. Univariate analysis showed that the plasma TAFI levels are significantly and inversely correlated with the glucose infusion rate (GIR) (
r
=
−0.42,
p
<
0.005) in all diabetic patients. Moreover, the plasma levels of TAFI were significantly correlated with fasting plasma glucose levels (
r
=
0.47,
p
<
0.001) and HbA
1c (
r
=
0.38,
p
<
0.005) in all subjects. The plasma levels of PAI-1 were significantly and proportionally correlated with the visceral fat area (
r
=
0.42,
p
<
0.005) and body mass index (
r
=
0.33,
p
<
0.05). There was no significant correlation between plasma levels of TAFI and PAI-1 (
r
=
0.04). These results show that the plasma levels of TAFI and PAI-1 differently correlate with insulin resistance and visceral fat accumulation, suggesting that different factors are implicated in the plasma elevation of TAFI and PAI-1 in non-obese type 2 diabetes mellitus.]]></abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>16458385</pmid><doi>10.1016/j.diabres.2005.12.008</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2006-08, Vol.73 (2), p.150-157 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68594337 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Body Mass Index Carboxypeptidase B2 - blood Carboxypeptidase B2 - metabolism Diabetes Mellitus, Type 2 - metabolism Female Fibrinolysis Humans Insulin Resistance Intra-Abdominal Fat - anatomy & histology Male Middle Aged Obesity - metabolism Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - metabolism Type 2 diabetes mellitus Visceral fat |
| title | Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A30%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20metabolic%20correlations%20of%20thrombin-activatable%20fibrinolysis%20inhibitor%20and%20plasminogen%20activator%20inhibitor-1%20in%20non-obese%20type%202%20diabetic%20patients&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Kitagawa,%20Nagako&rft.date=2006-08-01&rft.volume=73&rft.issue=2&rft.spage=150&rft.epage=157&rft.pages=150-157&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2005.12.008&rft_dat=%3Cproquest_cross%3E68594337%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68594337&rft_id=info:pmid/16458385&rft_els_id=S0168822706000076&rfr_iscdi=true |